CAS 1141777-14-1

Emixustat

Description:

Emixustat is a synthetic small molecule primarily investigated for its potential therapeutic applications in treating retinal diseases, particularly age-related macular degeneration (AMD). It functions as a visual cycle modulator, specifically inhibiting the enzyme RPE65, which plays a crucial role in the regeneration of visual pigments in the retina. This inhibition can help reduce the accumulation of toxic byproducts in the retinal pigment epithelium, thereby protecting photoreceptors from degeneration. Emixustat is characterized by its ability to alter the visual cycle, which may lead to improved visual function in patients with certain retinal conditions. The compound has been studied in various clinical trials to assess its efficacy and safety profile. Its chemical structure includes specific functional groups that contribute to its biological activity, although detailed structural information is typically reserved for scientific literature. Overall, Emixustat represents a promising avenue in the field of ophthalmology, aiming to address unmet medical needs in retinal health.

Formula: C₁₆H₂₅NO₂

InChI: InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2/t16-/m1/s1

InChI key: InChIKey=WJIGGYYSZBWCGC-MRXNPFEDSA-N

SMILES: [C@H](CCN)(O)C1=CC(OCC2CCCCC2)=CC=C1

Synonyms:

• (αR)-α-(2-Aminoethyl)-3-(cyclohexylmethoxy)benzenemethanol
• ACU 4429
• Emixustat
• (R)-(+)-3-Amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol
• Benzenemethanol, α-(2-aminoethyl)-3-(cyclohexylmethoxy)-, (αR)-

Emixustat

CAS: 1141777-14-1

Emixustat, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro. a novel visual cycle modulator.

Formula: C₁₆H₂₅NO₂

Color and Shape: Solid

Molecular weight: 263.38

Ref: TM-T11188

Emixustat

CAS: 1141777-14-1

Emixustat is a chemical inhibitor that inhibits the activity of the cation channel TRPM1. TRPM1 is expressed in choroidal neovascularization and proliferative diabetic retinopathy. It also has shown potential as a diagnostic agent for these eye disorders. Emixustat has been shown to inhibit the production of growth factors, which may be a cause for its therapeutic effect in both congenital amaurosis and growth factor-related eye disorders. Emixustat is an investigational drug that has not been approved by the FDA yet, but it is currently in phase III clinical trials.

Formula: C₁₆H₂₅NO₂

Purity: Min. 95%

Color and Shape: Colourless To Yellow Liquid

Molecular weight: 263.38 g/mol

Ref: 3D-FE171071